OncoTherapy's lead project set to enter Phase II
This article was originally published in Scrip
Executive Summary
The Japanese bioventure OncoTherapy Science is to take its lead development project into Phase II clinical trials later this year following positive results in a domestic Phase I study. OTS102 is an angiogenesis-inhibiting therapy for colon and other cancers, which targets the VEGF receptor 2 over-expressed in tumour blood vessels. Its main component is KDR169, the main kinase domain receptor of VEGFR2, which induces cytotoxic T lymphocytes to attack tumour-associated neovascular endothelial cells expressing KDR. The Phase II programme should begin in the autumn, OncoTherapy said.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.